Zuzana Sekeyová | Formulation Science | Best Researcher Award

Published on by Top Pharmaceutical

Mrs. Zuzana Sekeyová | Formulation Science | Best Researcher Award

Slovak Academy of Sciences | Slovakia

Mrs. Zuzana Sekeyová is a highly accomplished virologist and microbiologist with extensive expertise in the study, diagnosis, and prevention of rickettsial and intracellular pathogens. She obtained her Bachelor’s and Master’s degrees in Virology from Comenius University, Bratislava, and completed her Ph.D. at the Faculty of Natural Sciences, Comenius University, focusing on the biology of Rickettsiae and related organisms at the Institute of Virology, Slovak Academy of Sciences. She advanced her knowledge through postdoctoral training at the University of Maryland, Department of Microbiology and Immunology, Baltimore, USA, and through multiple visiting research fellowships supported by the Deutsche Akademische Austauschdienst (DAAD) at Justus Liebig Universität, Giessen, Germany, and the WHO Collaborative Center for Rickettsial Reference and Research, CNRS UPRESA 6020, Marseille, France. She further enhanced her global expertise as a visiting research fellow with the Japan Society for the Promotion of Science at Obihiro University of Agriculture & Veterinary Medicine and the National Institute of Infectious Diseases in Tokyo, Japan.Mrs. Sekeyová began her career as a scientific assistant and young scientist at the Institute of Virology, Slovak Academy of Sciences, progressing to senior research scientist and deputy head of the Department of Rickettsiology, where she currently oversees the Laboratory for Diagnosis and Prevention of Rickettsial and Chlamydial Infections. She serves as an expert verifier for the Slovak National Accreditation Service under the Good Laboratory Practice Compliance Program and is a key member of the National Reference Center for Surveillance and Laboratory Diagnostics of Rickettsiae. She is also an internationally recognized expert in synthetic biology, participating in the Open Ended Online Forum and the Ad Hoc Technical Expert Group under the United Nations Convention on Biological Diversity.Her research emphasizes the molecular biology, epidemiology, and diagnostics of rickettsial and related intracellular microorganisms, contributing to innovative detection methods and preventive strategies. Notable publications include Evaluation of cytotoxic activity against A549 human lung cancer cells using green synthesized N-Cholyl D-Penicillamine encapsulated silver and gold nanoparticles, Mucoadhesive and drug release of cholic acid based thiomeric micelles and encapsulated silver and gold nanoparticles for anticancer studies, and C-type natriuretic peptide induces cell death and sensitizes the effect of cisplatin in human non-small cell lung cancer cells. Through decades of research, Mrs. Sekeyová has combined rigorous laboratory investigations with translational and global health applications, establishing herself as a leading authority in virology, rickettsial diseases, and synthetic biology, with a strong commitment to advancing international scientific collaboration and public health initiatives.

Profile: Orcid

Featured Publications

Špitalská, E., Sabaka, P., Komorníková, A., Minichová, L., Palkovičová, K., Fenollar, F., Škultéty, Ľ., Miková, E., Sekeyová, Z., & Fournier, P.-E. Abdominal manifestations of Q fever. International Journal of Infectious Diseases.

Danchenko, M., Benada, O., Škultéty, Ľ., & Sekeyová, Z. Culture Isolate of Rickettsia felis from a Tick. International Journal of Environmental Research and Public Health.

Sekeyová, Z. Case studies of rickettsiosis, anaplasmosis and Q fever in Slovak population from 2011 to 2020. Biologia.

Sekeyová, Z. Detection of Rickettsia raoultii in Dermacentor reticulatus and Haemaphysalis inermis ticks in Slovakia. Biologia.

Sekeyová, Z. Hymenopteran Parasitoids of Hard Ticks in Western Africa and the Russian Far East. Microorganisms.

Gopinath Nagaraj | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Gopinath Nagaraj | Pharmacology | Best Researcher Award

University of Madras | India

Dr. Gopinath Nagaraj is an accomplished biochemist and molecular biologist specializing in cardiovascular research, with a particular focus on elucidating the molecular mechanisms underlying cardiac hypertrophy and heart failure. He earned his Ph.D. in Biochemistry from the University of Madras under the mentorship of Prof. Elangovan Vellaichamy, where his doctoral research explored the intricate molecular pathways governing cardiac hypertrophy through both in vitro and in vivo models. His expertise encompasses a wide range of cellular and molecular biology techniques, including qPCR, Western blotting, ELISA, FACS analysis, and fluorescence microscopy, all of which he has skillfully applied to investigate receptor signaling mechanisms and molecular cardiology.Dr. Gopinath’s pioneering research centers on the natriuretic peptide receptor-A (NPR-A/GC-A) signaling pathway and its modulation in cardiovascular physiology. His studies provide valuable insights into how NPR-A expression, internalization, and trafficking dynamics regulate receptor function and contribute to cardiovascular homeostasis. Through his innovative integration of experimental and computational methods—such as molecular docking and receptor trafficking assays—he has advanced understanding of how natural compounds like curcumin modulate receptor function and restore cellular signaling in stress-induced cardiac hypertrophy and inflammation models. This approach bridges receptor biology with natural product pharmacology, opening new therapeutic possibilities for cardiovascular disease management.His notable publications include Triiodo-L-thyronine Downregulates Npr1 Gene Transcription in H9c2 Cells: Involvement of β-AR-ROS Signaling published in Endocrine; C-Type Natriuretic Peptide Induces Cell Death and Sensitizes the Effect of Cisplatin in Human Non-Small Cell Lung Cancer Cells in International Journal of Peptide Research and Therapeutics; CNP Inhibits T3-Induced Hypertrophic Growth in H9c2 Cells: Impact of HDAC Inhibitor in Archives of Biochemistry and Biophysics; Curcumin with ANP Treatment Enhances the Internalization and Trafficking of NPR-A Mediated Signaling Pathway in Tissue and Cell; and Epigenetic Modulation of Natriuretic Peptide Receptor Signaling by HDAC Inhibitors in Thyroxine-Induced Cardiac Hypertrophy submitted to the European Journal of Pharmacology. Dr. Gopinath has contributed expert consultancy in receptor signaling and preclinical molecular evaluation for bioactive compounds, polymers, and nanoparticles with cardioprotective, anticancer, and anti-inflammatory properties. With multiple ongoing research projects, five publications in high-impact journals, and an h-index of three, he continues to strengthen the translational link between molecular cardiology and therapeutic innovation. His role as a reviewer for Discover Oncology further reflects his commitment to upholding scientific integrity and excellence in biomedical research. Through his innovative research, multidisciplinary collaborations, and translational insights, Dr. Gopinath exemplifies scientific dedication in advancing cardiovascular and molecular biosciences.

Profile: Google Scholar

Featured Publications

Elumalai, M., Nagaraj, G., Kasthuri, J., Vellaichamy, E., & Rajendiran, N. Evaluation of cytotoxic activity against A549 human lung cancer cells using green synthesized N-Cholyl D-Penicillamine encapsulated silver and gold nanoparticles. Inorganic Chemistry Communications, 153, 110834.

Baskaran, A., Elumalai, M., Nagaraj, G., Vellaichamy, E., & Rajendiran, N. Mucoadhesive and drug release of cholic acid-based thiomeric micelles and encapsulated silver and gold nanoparticles for anticancer studies. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 703, 135363.

Nagaraj, G., Dhanusu, S., Nachiappan, D. M., & Vellaichamy, E. C-type natriuretic peptide (CNP) induces cell death and sensitizes the effect of cisplatin in human non-small cell lung cancer cells (A549). International Journal of Peptide Research and Therapeutics, 28(4), 112.

Nagaraj, G., & Vellaichamy, E. Triiodo-L-thyronine (T3) downregulates Npr1 gene (coding for natriuretic peptide receptor-A) transcription in H9c2 cells: involvement of β-AR-ROS signaling. Endocrine, 85(3), 1075–1090.

Nagaraj, G., & Vellaichamy, E. CNP inhibits T3-induced hypertrophic growth in H9c2 cells: Impact of HDAC inhibitor. Archives of Biochemistry and Biophysics, 110648.

Elumalai, M., Nagaraj, G., Ramaraj, S. G., Vellaichamy, E., Tabata, H., & Rajendiran, N. NCPA-templated red-emitting gold nanoclusters: a turn-off-on fluorescent probe for rapid and selective detection of Cu²⁺ ions in live cells and evaluation of biological applications. Dalton Transactions (Cambridge, England: 2003).

Galal Elgemeie | Medicinal Chemistry | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. Galal Elgemeie | Medicinal Chemistry | Best Researcher Award

Helwan University | Egypt

Prof. Elgemeie stands as a distinguished figure in the field of organic and medicinal chemistry, with a research career deeply rooted in the development and mechanistic understanding of organic reactions and their applications in synthesizing antimetabolic agents. His scholarly pursuits bridge fundamental chemistry with biomedical innovation, particularly in the discovery of novel therapeutic compounds aimed at combating cancer and viral diseases. Through his extensive academic contributions, he has established a legacy of excellence that continues to inspire scientists and researchers globally.An internationally recognized scientist, Prof. Elgemeie was elected as a member of the Scientific Board of the International Basic Sciences Programme (IBSP) under UNESCO in Paris, France, reflecting his global influence and leadership in advancing the chemical sciences. His postdoctoral experiences across Germany, the United States, and England—supported by prestigious foundations such as the Alexander von Humboldt Foundation, the Fulbright Program, and the British Council—shaped his multidisciplinary expertise and broadened his research collaborations across continents.Prof. Elgemeie’s innovative research has led to numerous impactful projects, including the design and synthesis of novel epigenetic small molecules and antimetabolites in collaboration with the Institute of Medicinal Chemistry, Düsseldorf University. His pioneering work in developing sofosbuvir analogues for treating hepatitis C virus (HCV) and hepatocellular carcinoma among Egyptian patients demonstrates his commitment to translating scientific discovery into therapeutic applications with real-world benefits.His publication record is exceptional, with over 270 papers indexed in international databases such as Scopus, and his scientific influence is further underscored by a significant citation index. He has authored influential scientific books with leading publishers like Elsevier, offering comprehensive insights into cancer metabolism and heterocyclic chemistry. Prof. Elgemeie also holds several patents in process, reflecting his drive to innovate beyond academia and contribute to industry-based advancements in medicinal chemistry.Serving as an editorial board member for prominent journals including Current Microwave Chemistry, he continues to guide the global scientific dialogue in his field. His collaborations span several institutions worldwide, reinforcing his reputation as a bridge between Egyptian and international research communities.Beyond research, Prof. Elgemeie has played a vital role in educational reform and academic development across Egypt and the Arab region. He has supervised multiple cooperative projects with the European Community under the TEMPUS programme, contributing to the restructuring of higher education and aligning it with international standards. These initiatives have significantly advanced institutional capacity and innovation within Mediterranean and Arab universities.

Profile: Orcid

Featured Publications

Azzam, R. A., Seif, M. M., El-Demellawy, M. A., & Elgemeie, G. H. (2025). Novel 2-substituted benzothiazole derivatives: Synthesis, in vitro and in silico evaluations as potential anticancer agents. RSC Advances.

Elgemeie, G. H., Fathy, N. M., & Shaarawi, S. I. (2024). Naphthyl cyanoketene N, S-acetals in glycoside synthesis: A new preparative route to a new class of N-naphthylcyanoacrylamide thioglycosides and their conversions to naphthyl–pyrazole hybrids. Nucleosides, Nucleotides & Nucleic Acids.

Abu-Zaied, M. A., Nawwar, G. A., & Elgemeie, G. H. (2024). Novel synthesis of a new class of substituted S-glycosylisothiourea derivatives and their conversion to 5-amino-1,2,4-triazoles. Synthetic Communications.

Metwally, N. H., Elgemeie, G. H., & Fahmy, F. G. (2023). Synthesis and biological evaluation of benzothiazolyl-pyridine hybrids as new antiviral agents against H5N1 bird flu and SARS-CoV-2 viruses. ACS Omega.

Abdallah, A. E. M., Abdel-Latif, S. A., & Elgemeie, G. H. (2023). Novel fluorescent benzothiazolyl-coumarin hybrids as anti-SARS-COVID-2 agents supported by molecular docking studies: Design, synthesis, X-ray crystal structures, DFT, and TD-DFT/PCM calculations. ACS Omega.

Ahmed, E. A., Elgemeie, G. H., & Azzam, R. A. (2023). Synthesis of new sulfapyrimidine and pyrazolo[1,5-a]pyrimidine derivatives. Synthetic Communications.

Khedr, M. A., Zaghary, W. A., Elsherif, G. E., Azzam, R. A., & Elgemeie, G. H. (2023). Purine analogs: Synthesis, evaluation and molecular dynamics of pyrazolopyrimidines-based benzothiazole as anticancer and antimicrobial CDK inhibitors. Nucleosides, Nucleotides & Nucleic Acids.

Faiza Abou El-Soud | Formulation Science | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Faiza Abou El-Soud | Formulation Science | Best Researcher Award

College of Nursing-Riyadh King Saud bin Abdulaziz University for Health Sciences | Saudi Arabia

Prof. Faiza Abou El-Soud is a distinguished scholar and nursing educator whose work focuses on advancing health outcomes, improving the quality of patient care, and enriching the academic development of nursing students. With extensive expertise in nursing education, geriatric care, and psychosocial health, Professor Abou El-Soud has built a research portfolio that bridges theoretical understanding with practical application in healthcare and nursing practice. Her scholarly contributions reflect a commitment to evidence-based nursing, patient-centered care, and the empowerment of healthcare professionals through research-driven insights.Among her notable works is Nursing Students’ Perceptions toward Success and Failure Factors and their Academic Performance: A Descriptive Correlational Study, published in SYLWAN, which explores the academic determinants influencing nursing students’ success, offering valuable perspectives for educators seeking to improve nursing education outcomes. Another significant contribution, Impact of Self-Efficacy Theory on Improving Adherence of Older Adults Patients with Glaucoma’s Medication, published in the Journal of Health, Medicine and Nursing, applies psychological theory to practical nursing interventions, highlighting how self-efficacy principles can enhance medication adherence among older adults suffering from glaucoma.Professor Abou El-Soud has also made important contributions to geriatric health and community nursing through her publication Quality of Life, Self-Rated Health and Social Support among Older Adult in the Saudi Community in The Malaysian Journal of Nursing, where she and her co-authors assess the complex interplay between social support, perceived health, and overall life satisfaction among elderly populations. In another influential study, The Relationship between Health-Related Quality of Life and Burden among Family Caregivers of Elderly Patients Undergoing Hemodialysis in Saudi Arabia, published in the International Journal of Nursing Research, she investigates the emotional and physical challenges faced by caregivers, offering actionable insights to enhance support systems and healthcare strategies.Her collaborative work Impact of the Intrinsic and Extrinsic Motivation Factors on the Turnover Intention among Academic Staff, published in the IOSR Journal of Nursing and Health Science, examines motivational dynamics in academic environments and their influence on faculty retention, thereby contributing to the sustainability and advancement of nursing education institutions.

Profile: Google Scholar

Featured Publications

Salama, R. A., & Abou El-Soud, F. A. (n.d.). Caregiver burden from caring for impaired elderly: A cross-sectional study in rural Lower Egypt. Italian Journal of Public Health, 9(4), 103.

AlAnnaz, W. A. A., Gouda, A. D. K., Abou El-Soud, F. A., & Alanazi, M. R. (n.d.). Obesity prevalence and its impact on maternal and neonatal outcomes among pregnant women: A retrospective cross-sectional study design. Nursing Reports, 14(2), 1236–1250.

Hussein, A. A., & El-Soud, F. A. A. (n.d.). Developing an educational intervention and a standardized clinical assessment tool to promote clinical instructors assessment skills. The Fifteenth National Conference Evidence Based Practice.

Shaqiqi, W., & Abou El-Soud, F. A. (n.d.). The mediating role of social support on the relationship between secondary traumatic stress and burnout of nurses caring for COVID-19 patients: A cross-sectional study. Applied Nursing Research, 79, 151844.

Abou El-Soud, F. A., Alhoraim, S. A., Alammar, B. A., & Alotaibi, R. S. (n.d.). Quality of life, self-rated health and social support among older adult in the Saudi community. The Malaysian Journal of Nursing, 11(3), 13–25.

Al-Shehhi, M. S. M., & El-Soud, F. A. A. (n.d.). Factors affecting quality of life in patients with end-stage renal disease on hemodialysis, Ras Al Khaimah – United Arab Emirates. Journal of Health, Medicine and Nursing, 220–238.

Abou-El-Soud, F. A., Mohamed, H. F., & Prince, J. (n.d.). The effectiveness of training workshop in changing the tutors’ knowledge and attitude towards the integration of problem-based learning into nursing curriculum. International Journal of Nursing, 5.

Maria José García | Gastrointestinal Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Mrs. Maria José García | Gastrointestinal Pharmacology | Best Researcher Award

Hospital Universitario Marqués de Valdecilla | Spain

Mrs. María José García is a distinguished gastroenterologist renowned for her pioneering contributions to the understanding and treatment of inflammatory bowel diseases (IBD) and related gastrointestinal disorders. Currently serving as FEA Digestivo at the Hospital de Laredo, she has earned recognition as an accomplished clinician, educator, and researcher, with a strong commitment to advancing evidence-based gastroenterology. Her academic journey began with a degree in Medicine and Surgery from the University of Salamanca, followed by doctoral training in Biomedicine and Health Sciences at the University of Cantabria. This academic foundation, combined with her dedication to clinical excellence, has positioned her among the most respected figures in the field of digestive health.Her professional path includes prestigious international fellowships at Saint-Antoine Hospital in Paris and the Academic Medical Center in Amsterdam, where she deepened her expertise in the diagnosis and management of complex gastrointestinal conditions. These experiences allowed her to collaborate with leading European experts and integrate cutting-edge therapeutic innovations into clinical practice. Mrs. García’s research has been instrumental in shaping modern therapeutic approaches for IBD, particularly in evaluating biologic agents, third-line rescue therapies, and the withdrawal of antitumour necrosis factor treatments in patients achieving remission.Throughout her career, she has authored and co-authored numerous high-impact scientific articles published in prestigious journals such as Gut, Alimentary Pharmacology & Therapeutics, Therapeutic Advances in Gastroenterology, and Digestive and Liver Disease. Her most influential works have examined topics including inflammatory pouch disorders, safety and efficacy of advanced biologic therapies, and comparative analyses between novel treatment modalities for Crohn’s disease and ulcerative colitis. These studies have contributed valuable insights into optimizing patient care and personalizing treatment strategies across diverse clinical settings.Mrs. García’s scientific impact is underscored by an impressive record of 656 citations from 602 documents, 48 published papers, and an h-index of 14, reflecting both the quality and reach of her research. Her work continues to influence the global gastroenterology community, inspiring ongoing innovation and collaboration. Beyond research, she actively engages in knowledge dissemination through national and international conferences, promoting the integration of clinical practice with scientific discovery. Mrs. María José García stands as a model of excellence in gastroenterology—uniting clinical skill, academic rigor, and compassionate care to enhance the lives of patients worldwide.

Profile: Scopus

Featured Publications

Authors. (2025). Persistence, effectiveness, and safety of upadacitinib in Crohn’s disease and ulcerative colitis in real life: Results from a Spanish nationwide study (Ureal Study). American Journal of Gastroenterology.

Authors. (2025). Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: A randomised placebo-controlled clinical trial of GETECCU. Gut.

Authors. (2025). Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU. Digestive and Liver Disease.

Authors. (2025). Exploration of fecal microbiota in newly diagnosed patients with inflammatory bowel disease using shotgun metagenomics. Frontiers in Cellular and Infection Microbiology.

Feng Jiang | Cardiovascular Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Feng Jiang | Cardiovascular Pharmacology | Best Researcher Award

Stanford University | United States

Dr. Feng Jiang is a highly accomplished postdoctoral researcher at Stanford University, specializing in uncovering the mechanisms and risk factors of human autoimmune diseases. His research focuses on performing experiments and bioinformatic analyses on genetic and RNA-seq data to identify key disease mechanisms and develop therapeutics targeting these pathways. He has also established predictive models based on risk factors to enable early diagnosis of autoimmune conditions. Prior to his postdoctoral work, Dr. Jiang completed his Ph.D. at the University of Rochester, where he conducted extensive research targeting profibrotic genes to combat cardiac fibrosis. His work involved identifying common regulators controlling the expression of profibrotic genes, inhibiting their activity in animal models, and exploring the regulation of mRNA translation in cancer and heart disease. Additionally, he investigated the role of microRNAs in disease, identifying key microRNAs involved in disease progression and their potential as biomarkers for diagnosis and monitoring.Dr. Jiang also gained international research experience as a research fellow at Yat-sen University, where he executed sequencing library construction and established analysis pipelines for human and mouse samples. During his undergraduate studies at Wuhan University, he investigated the role of the gene GLIS2 in cancer progression using CRISPR/Cas9 gene editing techniques.He has contributed significantly to the scientific literature with numerous impactful publications, including works such as RNA Binding Protein PRRC2B Mediates Translation of Specific mRNAs and Regulates Cell Cycle Progression, Glutamyl-Prolyl-tRNA Synthetase Regulates Proline-Rich Pro-Fibrotic Protein Synthesis During Cardiac Fibrosis, Mammalian RNA Switches: Molecular Rheostats in Gene Regulation, Disease, and Medicine, MicroRNA574 Regulates FAM210A Expression and Influences Pathological Cardiac Remodeling, Correlation Between Severity of Spinal Stenosis and Multifidus Atrophy in Degenerative Lumbar Spinal Stenosis, Usage of Procalcitonin and sCD14-ST as Diagnostic Markers for Postoperative Spinal Infection, Correlations Between Serum P2X7, Vitamin A, 25-Hydroxy Vitamin D, and Mycoplasma Pneumoniae Pneumonia, Disruption of Tdrd5 Decouples the Stepwise Processing of Long Precursor Transcripts During Pachytene PIWI-Interacting RNA Biogenesis, and Cardiomyocyte-Specific Loss of Glutamyl-Prolyl-tRNA Synthetase Leads to Disturbed Protein Homeostasis and Dilated Cardiomyopathy.

Profile: Google Scholar

Featured Publications

Jiang, F., Hedaya, O. M., Khor, E. S., Wu, J., Auguste, M., & Yao, P. (n.d.). RNA binding protein PRRC2B mediates translation of specific mRNAs and regulates cell cycle progression. Nucleic Acids Research.

Wu, J., Subbaiah, K. C. V., Xie, L. H., Jiang, F., Khor, E. S., Mickelsen, D., Myers, J. R., Tang, W. H. W., & Yao, P. (n.d.). Glutamyl-prolyl-tRNA synthetase regulates proline-rich pro-fibrotic protein synthesis during cardiac fibrosis. Circulation Research.

Wu, J., Subbaiah, K. C. V., Jiang, F., Hedaya, O., Mohan, A., Yang, T., Welle, K., Ghaemmaghami, S., Tang, W. H. W., Small, E., Yan, C., & Yao, P. (n.d.). MicroRNA-574 regulates FAM210A expression and influences pathological cardiac remodeling. EMBO Molecular Medicine.

Subbaiah, K. C. V., Hedaya, O., Wu, J., Jiang, F., & Yao, P. (n.d.). Mammalian RNA switches: Molecular rheostats in gene regulation, disease, and medicine. Computational and Structural Biotechnology Journal.

Hedaya, O. M., Venkata Subbaiah, K. C., Jiang, F., Xie, L. H., Wu, J., Khor, E. S., Zhu, M., Mathews, D. H., Proschel, C., & Yao, P. (n.d.). Secondary structures that regulate mRNA translation provide insights for ASO-mediated modulation of cardiac hypertrophy. Nature Communications.

Xia, G., Li, X., Shang, Y., Fu, B., Jiang, F., Liu, H., & Qiao, Y. (n.d.). Correlation between severity of spinal stenosis and multifidus atrophy in degenerative lumbar spinal stenosis. BMC Musculoskeletal Disorders.

Zhu, X., Li, K., Zheng, J., Xia, G., Jiang, F., Liu, H., & Shi, J. (n.d.). Usage of procalcitonin and sCD14-ST as diagnostic markers for postoperative spinal infection. Journal of Orthopaedics and Traumatology.

Li, W., Li, Y., Jiang, F., & Liu, H. (n.d.). Correlation between serum levels of microRNA-21 and inflammatory factors in patients with chronic heart failure. Medicine.

Muneeb Ullah | Nanomedicine | Innovator in Pharmaceutical Research Award

Published on by Top Pharmaceutical

Mr. Muneeb Ullah | Nanomedicine | Innovator in Pharmaceutical Research Award

Pusan National University | South Korea

Mr. Muneeb Ullah is a dedicated pharmaceutical scientist and research assistant at the Department of Pharmacy, Pusan National University, Busan, South Korea. His academic journey reflects a strong foundation in pharmaceutics, nanomedicine, and advanced drug delivery systems. With a Doctoral pursuit in Pharmacy at Pusan National University, his research focuses on nanoparticle preparation and novel therapeutic approaches for biofilm-associated wound healing, colon cancer, inflammatory bowel disease, and diabetic wound healing.Mr. Ullah’s earlier academic achievements include an MPhil in Pharmaceutical Sciences with a specialization in Pharmaceutical Nanotechnology from Kohat University of Science and Technology (KUST), Pakistan, where he conducted advanced research on the development of polymeric nanoparticles using the water-in-oil emulsion solvent evaporation method. His Pharm-D degree from KUST provided a robust grounding in pharmaceutics, pharmacology, biochemistry, and pharmaceutical chemistry, further shaping his expertise in nanotechnology-based therapeutics.Throughout his academic and professional career, he has demonstrated exceptional dedication and excellence. He has received several honors, including the Higher Education Commission Indigenous Scholarship, the Prime Minister Laptop Scheme’s Best Talent Award, the Best Teacher Award, and multiple Best Researcher Awards. His multidisciplinary experience includes teaching, research supervision, and laboratory expertise encompassing nanoparticle synthesis, animal handling for wound healing studies, HPLC, ELISA, UV spectrophotometry, zeta sizer analysis, and confocal microscopy.Mr. Ullah’s research contributions have significantly advanced the field of pharmaceutical nanotechnology. His publications span reputable journals and book chapters with publishers such as CRC Press and Academic Press. His works explore diverse topics, including genetic engineering of fungi, sugar nanocluster adhesives for diabetic wound healing, advancements in 3D and 4D bioprinting for sustained drug delivery, biomedical applications of carbon dots, tumor microenvironment biology, gastrointestinal inflammation, and nanoparticle-based oral cancer therapies. His studies on alginate-based tumor-selective nanoparticle delivery and cancer nanomedicine have been widely cited for their innovation and translational potential.To date, Mr. Ullah has contributed to 37 scholarly documents, amassing a total of 470 citations, with an h-index of 11, reflecting the influence and recognition of his research in the global scientific community. With this growing research impact, he continues to contribute to cutting-edge pharmaceutical research with a vision to design smarter, safer, and more efficient nanotherapeutics that bridge the gap between laboratory innovation and clinical application.

Profile: Scopus

Featured Publications

Author(s). (2025). Leukocyte esterase-activated nanoconjugates enables precise local therapy of ulcerative colitis via inflamed tissue-selective drug delivery. ACS Applied Materials and Interfaces.

Author(s). (2025). Sugar nanocluster adhesive boosts wound healing in diabetic mice. Carbohydrate Polymer Technologies and Applications.

Author(s). (2025). Genetic engineering of fungi.

Rabab Abdel Moneim | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. Rabab Abdel Moneim | Personalized Medicine | Best Researcher Award

Cairo University | Egypt

Prof. Dr. Rabab Abdel Moneim is a distinguished authority in Clinical Oncology at the Kasr El Aini Faculty of Medicine, Cairo University, Cairo, Egypt. With an extensive career dedicated to cancer research, radiotherapy, and clinical practice, she has made a profound impact on oncology education, treatment innovation, and patient care across the Middle East. Her academic foundation was established at the renowned Kasr El Aini Faculty of Medicine, where she completed her M.B.B.Ch. degree with honors, followed by a master’s degree in Medical Oncology and Radiotherapy, earning the highest distinction across all Cairo universities. She later attained her Doctorate in Oncology, cementing her status as a leading scholar and clinician in the field.Prof. Abdel Moneim has accumulated rich professional experience through her long-standing affiliation with the Kasr El Aini Faculty of Medicine, where she has served in multiple academic and clinical capacities, advancing from house officer and resident to assistant lecturer, assistant professor, and eventually full professor. Her clinical expertise is reflected in her consultancy roles at the New Kasr El-Eini Teaching Hospital and the IMC Hospital Radiotherapy Center. Her early professional journey includes collaboration with Prof. Dr. Hamdy Abd El Azim at the Cairo Cure Center, a partnership that shaped her clinical vision and deepened her specialization in oncology and radiotherapy.Her professional experience extends beyond Egypt, having served as a consultant at King Fahd Hospital in Madina, Saudi Arabia, and maintaining an active registration with the Saudi Commission for Health Specialties in Oncology Medicine. Prof. Abdel Moneim’s commitment to global oncology advancement is further demonstrated through her participation in numerous international conferences and workshops, including ESMO, ESTRO, ASCO, and other major oncology congresses. Her contributions to evidence-based cancer therapy, radiotherapy techniques, and the facilitation of clinical trials across the MENA region have significantly influenced modern oncology practices.An active member of multiple professional societies such as ESTRO, ESMO, the Sarcoma Group, and the Neuro-Oncology Group at Cairo University, Prof. Abdel Moneim continues to contribute to academic excellence and clinical innovation. Her expertise in 3D conformal radiation therapy, stereotactic techniques, IMRT, and RapidArc has set a high standard in radiotherapy advancements. As a dedicated educator, she remains involved in postgraduate teaching and training programs, nurturing the next generation of oncologists.

Profile: Google Scholar

Featured Publications

Abdel Moneim, A. A. R., & El Deeb, M. (2017). Gingival pigmentation: Cause, treatment, and histological preview. Future Dental Journal.

Rady, D., Mubarak, R., & Abdel Moneim, R. A. (2018). Healing capacity of bone marrow mesenchymal stem cells versus platelet-rich fibrin in tibial bone defects of albino rats: An in vivo study. F1000Research.

Abdel Moneim, R. A., El Deeb, M., & Adel, F. (2018). Evaluation of the therapeutic potential of Tamarind seeds (aqueous extract) versus antidiabetic drugs on the histological structure of lingual papillae in diabetic rats. Egyptian Dental Journal, 64(3), Oral Medicine, X-Ray, Oral Biology Section.

Hakam, H. M., Abdel Moneim, R. A., & El Deeb, M. F. (2020). Osteoinductive potential and bone healing capacity of nanocrystalline hydroxyapatite (nHA) versus Biodentine of surgically created defects in rabbits’ alveolar process (an experimental study). Egyptian Journal of Histology.

Abdel Moneim, R. A., Mostafa, A., & Abbass, M. M. S. (2020). In treating glucocorticoid-induced osteoporosis in temporomandibular joint of albino rats; which are more effective: Microvesicles or mesenchymal stem cells? Egyptian Journal of Histology.

El Deeb, M., & Abdel Moneim, R. A. (2018). Remineralization potential of lactose-free and plant-based milk on enamel surface of human teeth subjected to energy drinks. Egyptian Dental Journal, 64(4), Oral Medicine, X-Ray, Oral Biology Section.

Ragaei, A., & Abdel Moneim, R. A. A. (2017). Gingival overgrowth: Drug-induced versus hereditary and idiopathic. Cosmetology & Oro Facial Surgery.

Biaoru Li | Personalized Medicine | Oncolog Oncopharm Research Achievement

Published on by Top Pharmaceutical

Dr. Biaoru Li | Personalized Medicine | Oncolog Oncopharm Research Achievement

Medical College of GA | United States

Dr. Biaoru Li is an accomplished leader in the fields of precision medicine, genomics, and personalized immunotherapy, with extensive experience spanning clinical hematology, oncology, and advanced molecular research. His expertise bridges the continuum from bio-specimen preparation to clinical application, integrating cutting-edge biobanking, primary cell sorting, single-cell identification, and functional genomics. Dr. Li’s research delves deeply into the cellular and molecular mechanisms that drive disease, with a particular focus on CD34 cells, erythroid cells, T-cells, and primary tumor cells. His work emphasizes the transformation of primary bio-specimens into powerful genomic insights through advanced technologies such as next-generation sequencing (NGS) and microarray analysis.A pioneer in precision medicine, Dr. Li has made substantial contributions to the development of personalized immunotherapy strategies and the integration of artificial intelligence into biomedical research. His ongoing projects include the design of AI-driven models that enhance diagnostic accuracy and therapeutic prediction for cancer and immune-related disorders. Dr. Li’s innovative research on single-cell RNA sequencing has opened new pathways for individualized treatment, offering a molecular-level understanding of disease heterogeneity.As an academic and clinical researcher, Dr. Li has established collaborations with hospitals and research institutions across the United States and Asia, promoting global scientific exchange and clinical translation. His scholarly impact is reflected in his numerous publications indexed in prestigious scientific databases such as SCI and Scopus, as well as his extensive citation record on Google Scholar and ORCID. Dr. Li’s editorial influence extends across 17 international editorial boards, where he contributes to advancing scientific standards in molecular medicine and clinical genomics.In addition to his academic achievements, Dr. Li has authored influential books, including Personalized Immunotherapy for Tumor Disease and Beyond and Personalized Therapy for PAH and Beyond, both of which underscore his leadership in developing targeted therapeutic frameworks. His membership in renowned professional societies, including the American Society of Hematology and the Royal Society of Medicine, underscores his commitment to advancing medical science and mentoring future researchers.

Profile: Orcid

Featured Publications

Li, S., & Li, B. (2025). Precision medicine related to landscape and architecture of tumor specimen. Japan Journal of Research.

Song, P., & Li, B. (2025). New generation of clinical epigenetics analysis and diagnosis for precision medicine. Diagnostics.

Palani, C. D., Smith, A., Cao, X., Li, B., Pace, B. S., & Starlard‐Davenport, A. (2025). Cholesterol‐conjugated miR‐29b induces fetal haemoglobin expression via γ‐globin promoter demethylation in the Townes mouse model for sickle cell anaemia. British Journal of Haematology.

Yang, Y., Chen, S., Li, W., Duan, J. C., Yuan, Y., Xie, V. S., & Li, B. (2024). STAT3 down-regulation for IL-2 inducing TIL-A clinical clue for spatial quantitative pathway analysis. AIMS Allergy and Immunology.

Li, B. (2024). Surgery and specimen biobanks—Tumor tissues and precision medicine. Journal of Surgery.

Li, B. (2024). Prediction, prevention, prognostic and personalized therapy of ovarian cancer—Biomarkers and precision medicine. Biomedical Journal of Scientific and Technical Research.

Yang, Y., Li, W., Chen, S., Yuan, Y., & Li, B. (2023). Spatial-timely quantitative network analysis for TGF-β pathway of tumor infiltrating lymphocytes. Journal of Cancer Science and Clinical Therapeutics.

Zhu, X., & Li, B. (Eds.). (2023). Epigenetics in cancer: Mechanisms and drug development – Volume II. Frontiers Research Topics.

Li, B. (2023). Personalized immunotherapy of patients: Defining by single-cell RNA-seq with artificial intelligence. Medical Research Archives.

Yunmeng Liu | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Assist. Prof. Dr. Yunmeng Liu | Immunotherapy | Best Researcher Award

University of Arkansas for Medical Sciences | United States

Dr. Yunmeng Liu is a highly accomplished biomedical scientist and pharmacologist specializing in the interplay between immunity, metabolism, and cardiovascular health. With a robust academic foundation in molecular biology and integrated biomedical science, Dr. Liu has devoted her career to unraveling the cellular and molecular mechanisms underlying hypertension, diabetes, and related cardiovascular complications. She currently serves as a Research Assistant Professor in the Department of Pharmacology and Toxicology at UAMS, where she leads innovative projects exploring the immune system’s role in metabolic and cardiovascular diseases. Her research integrates advanced techniques in pharmacology, immunology, and molecular biology to develop new therapeutic strategies for complex chronic conditions.Dr. Liu’s extensive research contributions are reflected in numerous high-impact publications. She has investigated P2X7-mediated activation of CD8+ T cells and their role in promoting salt-sensitive hypertension, providing critical insights into the immune modulation of blood pressure. Her work on interferon gamma pathways enhancing CD8 T cell interactions in hypertension and the stimulation of the Na-Cl co-transporter NCC by CD8+ T cells in distal convoluted tubules highlights the molecular crosstalk between immune cells and renal physiology. She has also explored immune dysregulation connecting type 2 diabetes and cardiovascular complications, emphasizing how chronic metabolic imbalances influence immune cell behavior and disease progression.Other notable contributions include the role of KATP channel openers in inhibiting lymphatic contractions and lymph flow as a mechanism of peripheral edema, and Eplerenone-mediated attenuation of fibrosis in the contralateral kidney by preventing macrophage-to-myofibroblast transition, which underscore her translational approach bridging basic research and clinical relevance. Additionally, she has advanced knowledge on resident-memory T cell establishment anchoring hypertension in the kidney and the nutrition impact on diabetes and cardiovascular health, reflecting her commitment to holistic understanding of disease mechanisms.Beyond her research, Dr. Liu is deeply engaged in education and mentorship, instructing graduate students in courses such as cell biology, pathologic basis of disease, and pharmacology and therapeutics, while supervising numerous PhD and undergraduate students in cutting-edge biomedical research projects. Her scholarly excellence is recognized through awards, grant funding, and memberships in professional societies including the American Heart Association, American Diabetes Association, and American Association of Immunologists, solidifying her status as a leading expert in immunopharmacology and cardiovascular-metabolic research.

Profile: Orcid

Featured Publications

Deck, K., Mora, C., Deng, S., Rogers, P., Rafferty, T., Palade, P. T., Mu, S., & Liu, Y. (2025). Immune dysregulation connecting type 2 diabetes and cardiovascular complications. Life, 15(8), 1241.

Liu, Y. (2024, May 29). Immune disorders connecting type 2 diabetes and cardiovascular complications [Preprint].

Benson, L., Deck, K., Mora, C., Guo, Y., Rafferty, T. M., Li, L.-X., Huang, L., Qin, Z., Andrews, J. T., & Liu, Y. (2024, January 9). P2X7-mediated antigen-independent activation of CD8 T cells promotes salt-sensitive hypertension. Hypertension (Dallas, Tex.: 1979).

Benson, L. N., Guo, Y., Deck, K., Mora, C., Liu, Y., & Mu, S. (2023, March 9). The link between immunity and hypertension in the kidney and heart. Frontiers in Cardiovascular Medicine, 10, 1129384.

Benson, L. N., Liu, Y., Deck, K., Mora, C., & Mu, S. (2022, October 26). IFNγ contributes to the immune mechanisms of hypertension. Kidney360, 3(10), 1234–1246.